User:Mr. Ibrahem/Alemtuzumab

Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein or under the skin.

Common side effects include low blood cells, infusion reactions, infection, nausea, diarrhea, and trouble sleeping. People taking the medication should not get live vaccines. Use in pregnancy may harm the baby. It is a monoclonal antibody that binds to CD52, a protein present on lymphocytes, resulting in their destruction.

Alemtuzumab was approved for medical use in the United States and Europe in 2001. The brand approved for CLL in Europe; however, was withdrawn while a new brand was approved for MS. In the United Kingdom a via of 12 mg costs the NHS about £7,000 as of 2021. This amount in the United States is about 27,700 USD.